Knight Reports Fourth Quarter and Year-Ended December 31, 2015 Results
(firmenpresse) - MONTREAL, CANADA -- (Marketwired) -- 03/24/16 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"), a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year-ended December 31, 2015.
2015 Highlights
Subsequent to the Year Ended December 31, 2015 Highlights
Financial Results Reported in Thousands of Canadian Dollars
For the quarter ended December 31, 2015, the Company reported revenue of $343 and net income of $5,554. For the year ended December 31, 2015, the Company reported revenue of $1,037 and net income of $34,167. As at December 31, 2015, the Company had $471,207 in cash, cash equivalents and marketable securities and 103,474,367 common shares outstanding.
"In 2015, we deployed or committed over $70 million in low risk, fair return opportunities while making substantial progress towards selling innovative products that touch the lives of patients. To that end, Knight now has secured the rights to a basket of over 20 products in various stages of development for Canada," said Jonathan Ross Goodman, President and CEO of Knight Therapeutics Inc. "In the year ahead, we will continue to focus on acquiring new product rights that improve the health of Canadians and work toward bringing our pipeline to market."
Conference Call Notice
Knight will host a conference call to discuss its fourth quarter and year end results today at 8:30 am ET. Investors and other interested parties may call 1-877-223-4471 (Operator Assisted Toll-Free) or 647-788-4922 (local or international).
A taped replay of the conference call will be available from today at 11:30 a.m. ET until Thursday, April 21, 2016 at 11:59 p.m. ET. To access the replay, please call 1-800-585-8367 or 416-621-4642 and use access code 79492415.
Notice of First Quarter 2016 Results
Knight expects to release its first quarter 2016 financial results on the morning of Tuesday, May 10, 2016. Knight expects to hold a conference call at 8:30 am ET on the morning of the release. All interested parties are cordially invited to attend. Investors and other interested parties may call 1-877-223-4471 (Operator Assisted Toll-Free) or 647-788-4922 (local or international).
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.''s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company''s web site at or .
Forward-Looking Statement
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.''s Annual Report and in Knight Therapeutics Inc.''s Annual Information Form for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.
CONSOLIDATED BALANCE SHEETS
(In thousands of Canadian dollars)
As at December 31
Knight Therapeutics Inc.
CONSOLIDATED STATEMENTS OF INCOME
(In thousands of Canadian dollars, except for share and per share amounts)
Year ended December 31
Knight Therapeutics Inc.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands of Canadian dollars)
Year ended December 31
Knight Therapeutics Inc.
CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS'' EQUITY
(In thousands of Canadian dollars)
Knight Therapeutics Inc.
CONSOLIDATED STATEMENT OF CASH FLOWS
(In thousands of Canadian dollars)
Year ended December 31
The following amounts are classified within operating activities:
Contacts:
Knight Therapeutics Inc.
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
514-484-GUD1 (4831)
514-481-4116 (FAX)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.03.2016 - 05:00 Uhr
Sprache: Deutsch
News-ID 1423838
Anzahl Zeichen: 2232
contact information:
Contact person:
Town:
MONTREAL, CANADA
Phone:
Kategorie:
Drugs
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Knight Reports Fourth Quarter and Year-Ended December 31, 2015 Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
Knight Therapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
